Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.67 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.54 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.54 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.54 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.54 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.54 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.54 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.54 |
| ▸ | KIF11 | P52732 | 1/20 | 0.53 |
| ▸ | GRM8 | O00222 | 1/20 | 0.50 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.50 |
| ▸ | ANPEP | P15144 | 2/20 | 0.49 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.49 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.49 |
| ▸ | LAP3 | P28838 | 1/20 | 0.49 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9394667 | 1.00 | SLC7A5 (0.67) | SLC7A5GRIK1GRIA1GRIA2GRIA3 | |
| SCHEMBL1666620 | 1.00 | SLC7A5 (0.67) | SLC7A5GRIK1GRIA1GRIA2GRIA3 | |
| Bromide SCHEMBL29399073 | 0.98 | SLC7A5 (0.65) | SLC7A5GRIK1GRIA1GRIA2GRIA3 | |
| Bromide SCHEMBL919214 | 0.98 | SLC7A5 (0.65) | SLC7A5GRIK1GRIA1GRIA2GRIA3 | |
| SCHEMBL1666513 | 0.90 | SLC7A5 (0.56) | SLC7A5GRIK1GRIA1GRIA2GRIA3 | |
| Homophenylalanine SCHEMBL1318350 | 0.89 | SLC7A5 (0.73) | SLC7A5GRIK1GRIA2KIF11ANPEP | |
| SCHEMBL22851020 | 0.86 | SLC7A5 (0.51) | SLC7A5GRIK1GRIA1GRIA2GRIA3 | |
| SCHEMBL23700720 | 0.85 | SLC7A5 (0.52) | SLC7A5ANPEPERAP2ERAP1LAP3 | |
| SCHEMBL3629108 | 0.85 | GRIK1 (0.54) | SLC7A5GRIK1GRIA1GRIA2GRIA3 | |
| SCHEMBL6377896 | 0.85 | GRIK1 (0.54) | SLC7A5GRIK1GRIA1GRIA2GRIA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 856 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12616761-B2 | CXCR4-targeting compounds | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2026-05-05 | — | — | US | claimed |
| US-12590123-B2 | Compounds and methods for treating cancer, viral infections, and allergic conditions | WASHINGTON UNIVERSITY (US) | 2026-03-31 | — | — | US | claimed |
| US-20260035408-A1 | WKYMVm peptide analogues having six residues and uses thereof | RESEARCH & BUSINESS FOUND SUNGKYUNKWAN UNIV (KR) | 2026-02-05 | — | — | US | claimed |
| EP-4633657-A1 | STAPLED PEPTIDES AND METHODS THEREOF | Parabilis Medicines, Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| EP-4633656-A1 | STAPLED PEPTIDES AND METHODS THEREOF | Parabilis Medicines, Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| US-20250296959-A1 | B7-H3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | MARIANA ONCOLOGY INC (US) | 2025-09-25 | — | — | US | claimed |
| US-20250276073-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TRANSFERRIN RECEPTOR 1 (TfR1) | BICYCLETX LIMITED (GB) | 2025-09-04 | — | — | US | claimed |
| US-20250242064-A1 | CXCR4-TARGETING COMPOUNDS, AND METHODS OF MAKING AND USING THE SAME | ALPHA-9 ONCOLOGY INC. (CA) | 2025-07-31 | — | — | US | claimed |
| US-12358948-B2 | Neurotensinergic agonists and methods of using same preventing or treating pain | SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) | 2025-07-15 | — | — | US | claimed |
| US-20250171495-A1 | MUTLI-TARGETED SERINE PROTEASE INHIBITORS FOR TREATMENT OF CANCER AND VIRAL INFECTION | WASHINGTON UNIVERSITY | 2025-05-29 | — | — | US | claimed |
| WO-2022177744-A1 | GIP/GLP1 DUAL AGONIST THERAPEUTIC METHODS | ELI LILLY AND COMPANY (US) | 2022-08-25 | — | — | WO | claimed |
| US-20220168383-A1 | NEUROTENSINERGIC AGONISTS AND METHODS OF USING SAME PREVENTING OR TREATING PAIN | SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) | 2022-06-02 | — | — | US | claimed |
| WO-2022094273-A1 | ANTIBACTERIAL CYCLOPEPTIDES TARGETING ACINETOBACTER AND OTHER GRAM-NEGATIVE PATHOGENS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2022-05-05 | — | — | WO | claimed |
| EP-3989997-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER, VIRAL INFECTIONS, AND ALLERGIC CONDITIONS | Washington University (US) | 2022-05-04 | — | — | EP | claimed |
| WO-2022082312-A1 | NOVEL CXCR4-TARGETING COMPOUNDS | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2022-04-28 | — | — | WO | claimed |
| WO-2022079031-A1 | REACTIVE CONJUGATES | DEBIOPHARM RESEARCH & MANUFACTURING S.A. (CH) | 2022-04-21 | — | — | WO | claimed |
| WO-2022078566-A1 | REACTIVE CONJUGATES | DEBIOPHARM RESEARCH & MANUFACTURING S.A. (CH) | 2022-04-21 | — | — | WO | claimed |
| US-20220089647-A1 | CYCLIC PEPTIDE, CELL SCAFFOLD MATERIAL, CELL SEPARATING MATERIAL, AND MEDIUM | FUJIFILM CORPORATION (JP) | 2022-03-24 | — | — | US | claimed |
| WO-2022052471-A1 | BISPECIFIC FUSION POLYPEPTIDE COMPOUND | 陕西麦科奥特科技有限公司 | 2022-03-17 | — | — | WO | claimed |
| EP-3967704-A1 | CYCLIC PEPTIDE, CELL SCAFFOLD MATERIAL, CELL SEPARATION MATERIAL AND CULTURE MEDIUM | FUJIFILM Corporation (JP) | 2022-03-16 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250242064-A1 | CXCR4-TARGETING COMPOUNDS, AND METHODS OF MAKING AND USING THE SAME | CXCR4, CXCL12, ACKR3 | SLC7A5 565/4885GRIK1 1539/4885GRIA1 1101/4885 |
| US-20250276073-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TRANSFERRIN RECEPTOR 1 (TfR1) | TFRC, SLC40A1, FOLR1 | SLC7A5 402/4885GRIK1 1586/4885GRIA1 383/4885 |
| US-12590123-B2 | Compounds and methods for treating cancer, viral infections, and allergic conditions | TMPRSS2, TMPRSS4, F2RL3 | SLC7A5 1719/4885GRIK1 1074/4885GRIA1 3244/4885 |
| US-20250171495-A1 | MUTLI-TARGETED SERINE PROTEASE INHIBITORS FOR TREATMENT OF CANCER AND VIRAL INFECTION | TMPRSS2, PRSS1, PRSS2 | SLC7A5 1732/4885GRIK1 3611/4885GRIA1 3165/4885 |
| US-20250296959-A1 | B7-H3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | CD274, CD44, CD74 | SLC7A5 843/4885GRIK1 3524/4885GRIA1 2624/4885 |
| US-12616761-B2 | CXCR4-targeting compounds | CXCR4, CXCR2, CXCR3 | SLC7A5 354/4885GRIK1 1369/4885GRIA1 523/4885 |
| US-20220089647-A1 | CYCLIC PEPTIDE, CELL SCAFFOLD MATERIAL, CELL SEPARATING MATERIAL, AND MEDIUM | CXCR3, XPA, LNPEP | SLC7A5 1218/4885GRIK1 2649/4885GRIA1 2794/4885 |
| US-20260035408-A1 | WKYMVm peptide analogues having six residues and uses thereof | HNMT, LTK, FPR3 | SLC7A5 99/4885GRIK1 1580/4885GRIA1 3136/4885 |
| US-12358948-B2 | Neurotensinergic agonists and methods of using same preventing or treating pain | VIP, NTSR2, VIPR2 | SLC7A5 2915/4885GRIK1 739/4885GRIA1 892/4885 |
| US-20220168383-A1 | NEUROTENSINERGIC AGONISTS AND METHODS OF USING SAME PREVENTING OR TREATING PAIN | VIP, NTSR2, VIPR2 | SLC7A5 2915/4885GRIK1 739/4885GRIA1 892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.